Eli Lilly and Company $LLY Shares Bought by AMF Tjanstepension AB

Key Points

• AMF Tjanstepension AB increased its Eli Lilly stake by 13.7% in the third quarter, adding 65,262 shares and bringing its holdings to 543,339 shares valued at approximately $628.7 million.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 and revenue of $22.97 billion, exceeding estimates and representing 47.7% year-over-year revenue growth.
• The stock traded down 2.4% despite largely positive analyst sentiment; Lilly has a “Moderate Buy” consensus rating and an average price target of $1,317.93, while insiders have sold shares under pre-arranged trading plans.

AMF Tjanstepension AB increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 543,339 shares of the company's stock after buying an additional 65,262 shares during the period. Eli Lilly and Company comprises approximately 3.7% of AMF Tjanstepension AB's investment portfolio, making the stock its 6th biggest holding. AMF Tjanstepension AB owned about 0.06% of Eli Lilly and Company worth $628,687,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Bank of America Corp DE purchased a new position in Eli Lilly and Company in the second quarter valued at about $13,522,666,000. Jupiter Topco LLC bought a new position in Eli Lilly and Company in the second quarter worth about $4,667,180,000. Fifth Third Bancorp lifted its position in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Corient Private Wealth LP purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $764,116,000. Finally, Diamant Asset Management Inc. lifted its position in shares of Eli Lilly and Company by 119,923.8% during the first quarter. Diamant Asset Management Inc. now owns 1,070,612 shares of the company's stock valued at $107,061,000 after buying an additional 1,069,720 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 2.4%

Shares of Eli Lilly and Company stock opened at $1,275.50 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12-month low of $809.63 and a 12-month high of $1,321.21. The firm has a market capitalization of $1.20 trillion, a price-to-earnings ratio of 42.80, a PEG ratio of 1.70 and a beta of 0.46. The firm's 50 day simple moving average is $1,186.64 and its two-hundred day simple moving average is $1,120.24.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. During the same quarter last year, the company posted $6.31 earnings per share. The business's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 33.22 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research note on Wednesday. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. TD Cowen restated a "buy" rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday, October 17th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,317.93.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement
• Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook
• Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update
• Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article
• Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview
• Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last quarter. 0.14% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.